Abstract: Disclosed are methods for improving compound detection and characterization. Methods for characterizing a sample are disclosed. The methods can include providing a sample to a liquid chromatography system capable of sample separation to generate sample components; analyzing sample components by multiplexed targeted selected ion monitoring (SIM) to generate an inclusion list; and performing iterative mass spectral data-dependent acquisition (DDA) from the inclusion list, to identify individual sample components thereby characterizing the sample. In one example, multiplexed targeted SIMs and iterative MS2 DDA acquisition is used to increase robust compound identification for cell culture medium analysis.

Abstract: The present invention pertains to methods for characterizing proteins in a sample using native capillary electrophoresis-mass spectrometry. The present invention pertains to methods for detecting and/or discriminating between post-translational modification variants of an antibody of interest in a sample, detecting and/or discriminating between antibodies in an antibody mixture, and characterizing monospecific antibody side products in a bispecific antibody sample.

Abstract: A practical and effective method for low abundance host cell protein (HCP) identification and quantification, which facilitates the downstream purification process in eliminating potentially problematic HCPs. In particular, the method comprises performing a native digestion followed by characterization using Multiple Reaction Monitoring approach.

Abstract: The present disclosure relates to a piperazine derivative, a preparation method therefor, and use thereof in medicine. Specifically, the present invention relates to a piperazine derivative represented by general formula (I), a preparation method therefor, and a pharmaceutically acceptable salt or prodrug thereof, and use thereof as a therapeutic agent, in particular, as an inhibitor of coagulation factor XIa (FXIa), wherein the definition of each substituent in general formula (I) is the same as that in the description.

Abstract: The present disclosure provides methods and compositions for the determining the abundance and/or concentration of protein biomarkers in a biological sample.

Abstract: The present invention generally pertains to methods of identifying and characterizing host cell proteins. In particular, the present invention pertains to the use of size exclusion chromatography in non-denaturing or denaturing conditions to enrich a sample for host cell proteins and characterize the binding of host cell proteins to a protein of interest.

Abstract: Compositions and methods for identifying free thiols in protein are provided. An exemplary method labeling peptides with a tag to identify free thiols and a tag to identify native disulfide bonds and analyzing the tags using targeted MS2. In one embodiment, the method provides complete coverage of all 32 cysteine residues in an IgG molecule. In other embodiments the method covers the 16 cysteine residues on the heavy and light chains in an IgG molecule. In another embodiment, the method covers the 5 cysteine residues on each light chain of an IgG molecule. In another embodiment, the method covers the 11 cysteine residues on each heavy chain of an IgG molecule.

Abstract: Compositions and methods for identifying free thiols in protein are provided. An exemplary method labeling peptides with a tag to identify free thiols and a tag to identify native disulfide bonds and analyzing the tags using targeted MS2. In one embodiment, the method provides complete coverage of all 32 cysteine residues in an IgG molecule. In other embodiments the method covers the 16 cysteine residues on the heavy and light chains in an IgG molecule. In another embodiment, the method covers the 5 cysteine residues on each light chain of an IgG molecule. In another embodiment, the method covers the 11 cysteine residues on each heavy chain of an IgG molecule.

Abstract: Methods for characterizing host-cell proteins in a sample matrix are provided.

Abstract: The present disclosure provides methods and compositions for the determining the abundance and/or concentration of protein biomarkers in a biological sample.

Abstract: The present invention pertains to methods for characterizing proteins in a sample using native capillary electrophoresis-mass spectrometry. The present invention pertains to methods for detecting and/or discriminating between post-translational modification variants of an antibody of interest in a sample, detecting and/or discriminating between antibodies in an antibody mixture, and characterizing monospecific antibody side products in a bispecific antibody sample.

Abstract: An image processing model can more accurately process a face image with an occluded face while reducing calculations and improving operation speed of a processing device, reducing training time and costs. A predicted recognition result of a sample face image and occlusion indication information based on an image processing model is obtained. The occlusion indication information indicates an image feature of a face occlusion area of the sample face image. A recognition error based on the predicted recognition result and a target recognition result is also obtained. A classification error is obtained based on the occlusion indication information and a target occlusion pattern corresponding to the sample face image. An occlusion pattern of the sample face image indicates a position and a size of the face occlusion area. A model parameter of the image processing model is updated based on the recognition error and the classification error.

Abstract: Methods for identifying viral protein constituents and quantifying the relative abundance of such viral protein constituents in a sample of viral particles are disclosed. In embodiments, the methods include first-dimension chromatography to separate intact viral capsid components of the sample, online denaturation of the viral capsid components to produce intact viral proteins, second-dimension chromatography to separate the viral proteins, and mass spectrometry to determine the masses of the viral proteins and identify the viral protein constituents of the sample.

Abstract: Disclosed are methods for improving compound detection and characterization. Methods for characterizing a sample are disclosed. The methods can include providing a sample to a liquid chromatography system capable of sample separation to generate sample components; analyzing sample components by multiplexed targeted selected ion monitoring (SIM) to generate an inclusion list; and performing iterative mass spectral data-dependent acquisition (DDA) from the inclusion list, to identify individual sample components thereby characterizing the sample. In one example, multiplexed targeted SIMs and iterative MS2 DDA acquisition is used to increase robust compound identification for cell culture medium analysis.

Abstract: The present invention provides stable liquid pharmaceutical formulations comprising a human bispecific antibody that specifically binds to human MUC16 and human CD3. In certain embodiments, the formulations contain, in addition to the bispecific antibody, a buffer, a surfactant, and a sugar. The pharmaceutical formulations of the present invention exhibit a substantial degree of antibody stability upon stress and storage.

Abstract: Embodiments provide for methods of predicting glycation percentage of an amino acid in a therapeutic biomolecule. In one example, a method of predicting a glycation percentage of an amino acid in a biomolecule includes determining a first set of rates for a de-glycation reaction for a first set of temperatures, inferring a second set of one or more rate(s) for the de-glycation reaction for a second set of temperatures, and using the second set of one or more rate(s) to predict the glycation percentage at any temperature corresponding to the second set of temperatures and over any time duration. Also provided are methods for maintaining a glycation percentage of an amino acid within a predetermined glycation percentage range over a shelf-life of a therapeutic biomolecule, and methods for either reducing or increasing a potency of a therapeutic biomolecule in a subject at a time of administration.

Abstract: The present invention relates to an alkyne derivative, a preparation method for same, and applications thereof in medicine. Specifically, the present invention relates to the alkyne derivative as represented by formula (I), the preparation method for same, a pharmaceutically acceptable salt thereof, and uses of them as a therapeutic agent, specifically as a phosphoinositide 3-kinase ? (PI3K?) inhibitor, where the definitions of the substituents in formula (I) are identical to the definitions in the description.

Abstract: This disclosure provides a method for evaluating volume responsiveness and a medical device. The medical device includes a respiratory assistance device for providing respiratory support for a patient, and a first sensor for collecting physiological parameters of the patient and a processor. When volume responsiveness evaluation is needed, the processor controls ventilation parameters to switch to a second ventilation parameter that may increase the variation of the intrathoracic pressure of the patient, and then uses a parameter variation capable of reflecting the heartbeat of the patient to evaluate whether the patient is volume responsive.

Abstract: Disclosed are methods for improving compound detection and characterization. Methods for characterizing a sample are disclosed. The methods can include providing a sample to a liquid chromatography system capable of sample separation to generate sample components; analyzing sample components by multiplexed targeted selected ion monitoring (SIM) to generate an inclusion list; and performing iterative mass spectral data-dependent acquisition (DDA) from the inclusion list, to identify individual sample components thereby characterizing the sample. In one example, multiplexed targeted SIMs and iterative MS2 DDA acquisition is used to increase robust compound identification for cell culture medium analysis.

Abstract: The present disclosure generally pertains to methods of identifying and quantitating host cell proteins (HCPs) in therapeutic protein development. In particular, the present invention generally pertains to methods of liquid chromatography-tandem mass spectrometry (LC-MS/MS) for unbiased identification and sensitive quantitation of HCPs in therapeutic protein development.